Encorafenib (BRAFTOVI®): A Comprehensive Pharmacological and Clinical Monograph

Section 1: Executive Summary & Drug Profile

Encorafenib, marketed under the brand name BRAFTOVI®, is an orally available, small-molecule kinase inhibitor that represents a significant advancement in the field of precision oncology.[1] It functions as a potent and selective inhibitor of the BRAF kinase, a key enzyme in the mitogen-activated protein kinase (MAPK) signaling pathway. The drug specifically targets cancers harboring activating mutations in the

BRAF gene, most notably the V600E and V600K substitutions, which act as oncogenic drivers in a variety of malignancies.[3]

The clinical utility of Encorafenib is defined by its use in rationally designed combination regimens. It is approved by regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of several advanced cancers. These indications include unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (in combination with the MEK inhibitor binimetinib), metastatic colorectal cancer (CRC) with a BRAF V600E mutation (in combination with the EGFR inhibitor cetuximab), and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation (in combination with binimetinib).[2]

The rationale for these combination strategies is rooted in the complex biology of the MAPK pathway. Combining Encorafenib with a downstream MEK inhibitor mitigates the paradoxical pathway activation often seen with BRAF inhibitor monotherapy, a mechanism that can promote the growth of wild-type BRAF cells and lead to secondary malignancies.[7] In colorectal cancer, the addition of an EGFR inhibitor is necessary to overcome intrinsic resistance mechanisms mediated by feedback loops involving the EGFR receptor.

Encorafenib possesses a complex pharmacokinetic profile characterized by auto-induction of its own metabolism, primarily through the cytochrome P450 3A4 (CYP3A4) enzyme system. This property underlies a significant potential for drug-drug interactions, requiring careful management of concomitant medications.[7] Key safety considerations associated with Encorafenib therapy include the risk of new primary cutaneous and non-cutaneous malignancies, hemorrhage, ocular toxicities such as uveitis, and cardiotoxicity, including QT interval prolongation.[7] Effective and safe use of Encorafenib therefore demands a nuanced understanding of its pharmacology, a commitment to biomarker-driven patient selection, and vigilant clinical monitoring.

Section 2: Physicochemical Properties and Molecular Identity

Establishing the precise identity of a therapeutic agent is fundamental to its study and clinical application. Encorafenib is a synthetic organic small molecule with a distinct chemical structure and set of properties that define its behavior as a pharmaceutical substance. It is referenced by numerous identifiers across chemical, clinical, and regulatory databases, which are consolidated here for clarity.

Drug Identification

Encorafenib is known by its generic name, various developmental codes, and its commercial brand name. Its classification as a BRAF kinase inhibitor places it within the broader category of antineoplastic agents and targeted cancer therapies.[9] The primary identifiers for Encorafenib are summarized in Table 1.

Chemical and Physical Properties

The chemical structure of Encorafenib is a complex carbamate ester containing pyrazole and pyrimidine rings. Its formal IUPAC name is Methylphenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate.[2] The molecule's activity is dependent on its specific stereochemistry, with the (S)-isomer being the active form.[1]

The molecular formula of Encorafenib is C22​H27​ClFN7​O4​S, corresponding to an average molecular weight of 540.01 g/mol and a monoisotopic mass of 539.1518 g/mol.[3] Its structure is represented by the SMILES string

O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1 and the InChIKey CMJCXYNUCSMDBY-ZDUSSCGKSA-N.[15]

Physically, Encorafenib is a crystalline solid.[16] Its solubility profile is critical for its formulation as an oral drug and for its use in research settings. It is reported to be soluble in organic solvents such as dimethyl sulfoxide (DMSO) at 20 mg/mL and dimethylformamide (DMF) at 25 mg/mL, and sparingly soluble in ethanol at 15 mg/mL. It is considered insoluble in water, a common characteristic of many orally administered small-molecule kinase inhibitors.[15] For long-term storage, it is recommended to be kept at -20°C in a dry, dark environment to ensure its stability, which is reported to be at least four years under these conditions.[15]

Property / Identifier	Value	Source(s)
Generic Name	Encorafenib	2
Brand Name	Braftovi®	2
Drug Class	Kinase Inhibitor, BRAF Kinase Inhibitor	7
DrugBank ID	DB11718	1
CAS Number	1269440-17-6	1
Developmental Codes	LGX818, NVP-LGX818	3
UNII	8L7891MRB6	1
ChEMBL ID	CHEMBL3301612	1
PubChem CID	50922675	2
KEGG ID	D11053	1
ATC Code	L01EC03	2
Molecular Formula	C22​H27​ClFN7​O4​S	3
Molecular Weight	540.01 g/mol (Average)	3
IUPAC Name	Methylphenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate	2
Physical Appearance	Crystalline Solid	16
Solubility	Soluble in DMSO, DMF; Insoluble in water	15
Storage Conditions	-20°C, dry, dark (long-term)	15

Table 1: Comprehensive Drug Identification and Physicochemical Properties of Encorafenib. This table provides a consolidated reference for the various identifiers and key physical and chemical characteristics of Encorafenib, synthesizing data from multiple sources to ensure unambiguous identification.

Section 3: Pharmacodynamics and Mechanism of Action

The therapeutic effect of Encorafenib is derived from its precise interaction with specific molecular targets within cancer cells. Its pharmacodynamic profile is characterized by high potency, a unique target residence time, and a class-specific liability that necessitates its use in combination therapy.

Primary Mechanism of Action

Encorafenib is an ATP-competitive, reversible inhibitor of RAF family kinases, which are serine/threonine kinases central to the RAS/RAF/MEK/ERK signaling cascade, commonly known as the MAPK pathway.[1] This pathway is a fundamental regulator of essential cellular processes, including proliferation, differentiation, survival, and angiogenesis.[1] In many cancers, this pathway becomes dysregulated. Somatic mutations in the

BRAF gene, particularly point mutations at codon 600 such as the valine-to-glutamic acid substitution (V600E), result in a constitutively active BRAF protein. This leads to persistent, uncontrolled signaling through the MAPK cascade, which drives oncogenesis and tumor growth.[3] Encorafenib is designed to specifically counteract this effect. By binding to the ATP-binding pocket of the BRAF kinase, it prevents the phosphorylation and activation of its downstream target, MEK, thereby interrupting the oncogenic signal.[16]

Potency and Selectivity

Encorafenib demonstrates remarkable potency against its intended targets. In cell-free assays, it inhibits the mutant BRAF V600E kinase with an IC50 value of 0.35 nM.[3] In cell-based assays, it suppresses the proliferation of BRAF V600E-mutant melanoma cells with an EC50 of 4 nM.[15] Its activity extends to other BRAF mutations, including V600D and V600K.[3]

A critical feature of Encorafenib's profile is its activity against wild-type kinases. It potently inhibits wild-type BRAF (IC50 = 0.47 nM) and CRAF (IC50 = 0.3 nM).[3] While it is highly selective against the broader kinome, showing minimal activity against a panel of over 100 other kinases (IC50s > 900 nM), its potent interaction with wild-type RAF kinases has profound mechanistic and clinical implications.[16]

Downstream Cellular Effects

The inhibition of BRAF by Encorafenib leads to a cascade of downstream effects. The blockade of MEK activation results in a marked reduction in the levels of phosphorylated ERK (pERK), the terminal kinase in the pathway.[20] This suppression of MAPK signaling leads to the downregulation of key cell cycle regulatory proteins, most notably Cyclin-D1.[2] The loss of Cyclin-D1 prevents cells from progressing through the G1/S checkpoint, causing them to arrest in the G1 phase of the cell cycle. This cell cycle arrest ultimately inhibits tumor cell proliferation and can induce cellular senescence and apoptosis (programmed cell death), leading to tumor regression.[2]

The Imperative for Combination Therapy: Paradoxical Activation

The potent inhibition of wild-type BRAF, while contributing to its overall activity, also creates a significant liability known as paradoxical MAPK pathway activation. This phenomenon is a class effect of many RAF inhibitors. In cells that are BRAF wild-type but harbor an upstream activating mutation (e.g., in a RAS gene), BRAF kinases exist as dimers. When an inhibitor like Encorafenib binds to one BRAF molecule in the dimer, it can induce a conformational change that allosterically transactivates the unbound partner molecule. This results in a paradoxical increase, rather than a decrease, in downstream MEK/ERK signaling.[8]

This mechanism is the biological basis for the observed clinical risk of developing new primary malignancies during treatment, particularly cutaneous squamous cell carcinomas (cuSCC), which are often driven by RAS mutations.[7] It also explains the explicit warning against using Encorafenib in patients with wild-type BRAF tumors, as it could paradoxically promote their growth.[8] This inherent liability of the drug class makes combination therapy a mechanistic necessity. By co-administering Encorafenib with a MEK inhibitor such as binimetinib, the MAPK pathway is blocked downstream of RAF. This dual blockade effectively shuts down the oncogenic signal, regardless of whether it originates from a mutant BRAF or from a paradoxically activated wild-type BRAF dimer. This strategy not only enhances anti-tumor efficacy but, critically, serves as a pharmacological countermeasure to a predictable, mechanism-based toxicity.

Target Residence Time

Another nuanced aspect of Encorafenib's pharmacodynamics is the relationship between its plasma concentration and its target engagement. The drug has a relatively short plasma elimination half-life of approximately 3.5 to 6 hours.[2] However, preclinical data indicate that it has a very long dissociation half-life from the RAF kinase, exceeding 30 hours.[19] This mismatch implies that Encorafenib remains tightly bound to its target, exerting a sustained inhibitory effect long after its concentration in the bloodstream has declined. This prolonged "target residence time" is a key pharmacodynamic property that likely contributes to the durable pathway suppression and supports the efficacy of a convenient once-daily dosing schedule, despite its rapid systemic clearance.

Section 4: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Encorafenib describes its movement into, through, and out of the body. Understanding these ADME properties is essential for determining appropriate dosing, anticipating drug interactions, and managing therapy in diverse patient populations.

Absorption

Encorafenib is administered orally and is well absorbed, with a bioavailability of at least 86%.[7] Following oral administration of a single dose, it reaches peak plasma concentration (Tmax) in approximately 2 hours.[7] The effect of food on its absorption has been studied; administration with a high-fat, high-calorie meal was found to decrease the peak concentration (Cmax) by 36%. However, this meal had no clinically meaningful effect on the total drug exposure, as measured by the area under the concentration-time curve (AUC).[7] This finding allows for flexible dosing, as the drug can be taken with or without food, enhancing patient convenience and adherence.[24]

Distribution

Once absorbed into the systemic circulation, Encorafenib is highly bound to plasma proteins, with a bound fraction of 86%.[7] It exhibits extensive distribution into the tissues, as indicated by its large apparent volume of distribution (Vd) of 164 L.[7] This suggests that the drug does not remain confined to the bloodstream and effectively reaches peripheral tissues where tumors may be located.

Metabolism and Auto-Induction

Encorafenib is primarily cleared from the body through extensive hepatic metabolism, with N-dealkylation being the principal metabolic pathway.[5] The cytochrome P450 (CYP) family of enzymes plays a central role in its biotransformation. In vitro studies using human liver microsomes have shown that

CYP3A4 is the main contributor to its oxidative clearance, accounting for approximately 83% of the process. Minor contributions are made by CYP2C19 (16%) and CYP2D6 (1%).[7] This heavy reliance on CYP3A4 makes Encorafenib highly susceptible to interactions with drugs that inhibit or induce this enzyme.

A critical pharmacokinetic feature of Encorafenib is its ability to induce its own metabolism. The drug is a moderate inducer of CYP3A4.[9] This leads to a phenomenon known as auto-induction, where continued administration of the drug increases the rate of its own clearance. This is evidenced by the observation that drug exposure at steady-state (reached within 15 days) is approximately 50% lower than the exposure observed on the first day of dosing.[3] Correspondingly, its systemic clearance increases from approximately 14 L/hr on Day 1 to 32 L/hr at steady-state.[7] This auto-induction mechanism is a crucial consideration, as it not only affects Encorafenib's own concentration over the initial weeks of therapy but also amplifies its potential to reduce the concentrations of other co-administered CYP3A4 substrate drugs.

Excretion

The elimination half-life (t½) of Encorafenib is relatively short, estimated to be between 3.5 and 6 hours.[2] A human mass balance study using radiolabeled [¹⁴C] encorafenib provided definitive information on its excretion routes. Following a single 100 mg oral dose, the recovery of radioactivity was nearly complete. The elimination was found to be almost equally divided between the feces (mean of 47.2% of the dose) and the urine (mean of 47.2% of the dose).[5] Very little of the parent drug was excreted unchanged (5% in feces, 2% in urine), confirming that metabolism is the predominant mechanism of elimination.[5]

Parameter	Value	Source(s)
Bioavailability	≥86%	7
Time to Peak Plasma Concentration (Tmax)	~2 hours	7
Effect of High-Fat Meal	Cmax ↓ 36%; AUC unchanged	7
Plasma Protein Binding	86%	7
Volume of Distribution (Vd)	164 L	7
Elimination Half-Life (t½)	3.5 - 6 hours	2
Systemic Clearance	Day 1: 14 L/hr; Steady-State: 32 L/hr	7
Primary Metabolic Pathway	N-dealkylation	7
Key Metabolizing Enzymes	CYP3A4 (83%), CYP2C19 (16%), CYP2D6 (1%)	7
Excretion Routes	Feces: 47% (5% unchanged); Urine: 47% (2% unchanged)	5

Table 2: Summary of Key Pharmacokinetic Parameters for Encorafenib. This table provides a quantitative overview of the absorption, distribution, metabolism, and excretion (ADME) profile of Encorafenib.

Section 5: Clinical Efficacy and Approved Indications

The clinical development of Encorafenib has successfully established its efficacy in several solid tumors characterized by specific BRAF mutations. Its approval in each indication is based on robust data from pivotal clinical trials demonstrating a significant improvement in patient outcomes. A key theme across its development is its "partner-dependent" efficacy, where its clinical utility is unlocked by combining it with another targeted agent that addresses the specific resistance biology of the cancer type.

5.1 Unresectable or Metastatic Melanoma (BRAF V600E/K Mutation)

Indication and Regimen: Encorafenib is indicated in combination with the MEK inhibitor binimetinib for the treatment of patients with unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation.[3] It is explicitly not indicated for patients with wild-type BRAF melanoma.[2]

Pivotal Trial: The approval for this indication was based on the results of the COLUMBUS (NCT01909453) trial, a large, randomized, active-controlled, open-label, multicenter Phase 3 study.[2] The trial was designed to evaluate the combination of Encorafenib (450 mg once daily) plus binimetinib (45 mg twice daily) compared with monotherapy using either vemurafenib or Encorafenib.

Efficacy Results: The combination of Encorafenib and binimetinib demonstrated statistically significant and clinically meaningful superiority over the BRAF inhibitor monotherapy control arm (vemurafenib). The primary endpoint, median progression-free survival (PFS), was more than doubled in the combination arm, reaching 14.9 months compared to 7.3 months for patients receiving vemurafenib alone (Hazard Ratio 0.54; 95% Confidence Interval [CI] 0.41-0.71; p<0.0001).[2] The combination also conferred a significant overall survival (OS) benefit, reducing the risk of death compared to vemurafenib treatment (HR 0.61; 95% CI 0.47-0.79; p<0.001).[25]

5.2 Metastatic Colorectal Cancer (BRAF V600E Mutation)

Indication and Regimen: In colorectal cancer, the biology of BRAF-mutant tumors differs from melanoma. BRAF inhibition alone is largely ineffective due to rapid feedback reactivation of the MAPK pathway through the epidermal growth factor receptor (EGFR). Therefore, Encorafenib is approved in combination with an EGFR inhibitor, cetuximab, for adult patients with metastatic CRC with a BRAF V600E mutation whose disease has progressed after prior therapy.[3] More recently, it gained accelerated approval for first-line treatment in combination with cetuximab and the mFOLFOX6 chemotherapy regimen.[2]

Pivotal Trial: The approval for the second-line setting was based on the BEACON CRC (NCT02928224) trial, a randomized, open-label, Phase 3 study.[26] This trial evaluated Encorafenib (300 mg once daily) plus cetuximab against a control arm of investigator's choice of standard chemotherapy (irinotecan or FOLFIRI) plus cetuximab.

Efficacy Results: The Encorafenib-based combination demonstrated superior outcomes. The median overall survival (OS) was 8.4 months for patients in the Encorafenib plus cetuximab arm, compared to 5.4 months in the control arm (HR 0.60; 95% CI 0.45-0.79; p=0.0003).[26] The combination also led to a significantly higher overall response rate (ORR) of

20% versus only 2% in the control arm (p<0.0001) and improved PFS (median 4.2 months vs. 1.5 months; HR 0.40).[26]

5.3 Metastatic Non-Small Cell Lung Cancer (NSCLC) (BRAF V600E Mutation)

Indication and Regimen: Similar to melanoma, the appropriate combination partner for Encorafenib in NSCLC is a MEK inhibitor. It is approved in combination with binimetinib for the treatment of adult patients with metastatic NSCLC with a BRAF V600E mutation.[3]

Supporting Trial: The approval was supported by the PHAROS (NCT03915951) trial, a single-arm, open-label study investigating the combination in this specific molecular subtype of lung cancer.[8] In the cohort of patients who were treatment-naïve, the combination showed profound activity, with an ORR of approximately 75% and a median PFS that was not reached at the time of an early analysis, later reported by the EMA to be 40 months.[28] These results highlight the potent anti-tumor activity of dual MAPK pathway blockade in this patient population.

Trial (Indication)	Encorafenib Regimen	Control Arm	Primary Endpoint	Median PFS (months)	PFS Hazard Ratio (95% CI)	Median OS (months)	OS Hazard Ratio (95% CI)	Overall Response Rate (%)
COLUMBUS (Melanoma)	Encorafenib + Binimetinib	Vemurafenib	PFS	14.9	0.54 (0.41-0.71)	33.6 (not primary)	0.61 (0.47-0.79)	64%
BEACON CRC (Colorectal Cancer)	Encorafenib + Cetuximab	Irinotecan/FOLFIRI + Cetuximab	OS	4.2	0.40 (0.31-0.52)	8.4	0.60 (0.45-0.79)	20%

Table 3: Summary of Efficacy Outcomes from Pivotal Clinical Trials of Encorafenib. This table compares the key efficacy results from the COLUMBUS and BEACON CRC trials, illustrating the magnitude of clinical benefit in Encorafenib's major approved indications and highlighting the different control arms and outcomes. (Note: OS was not the primary endpoint for COLUMBUS but was a key secondary endpoint; OS for Encorafenib + Binimetinib was 33.6 months).

Section 6: Safety, Tolerability, and Risk Management

While Encorafenib-based combination therapies offer significant efficacy benefits, they are associated with a distinct profile of adverse reactions that require careful monitoring and management. The safety profile reflects both on-target effects of MAPK pathway inhibition and mechanism-based off-target toxicities.

Common Adverse Reactions

Across clinical trials, the most frequently reported adverse reactions (occurring in ≥25% of patients) are generally consistent with the side effects of MAPK pathway inhibitors. These include constitutional symptoms and gastrointestinal issues such as fatigue, nausea, diarrhea, vomiting, and abdominal pain. Musculoskeletal complaints, particularly arthralgia (joint pain), are also very common.[2] While often low-grade, these side effects can significantly impact a patient's quality of life and may require symptomatic management.

Serious Warnings and Precautions

The prescribing information for Encorafenib includes several important warnings and precautions that highlight risks requiring proactive clinical management.

• New Primary Malignancies: This is a critical risk rooted in the paradoxical activation of the MAPK pathway in BRAF wild-type cells.
• Cutaneous Malignancies: Patients are at risk of developing new cutaneous squamous cell carcinoma (cuSCC), including its variant keratoacanthoma (KA), as well as basal cell carcinoma.[7] This necessitates regular dermatologic surveillance, including a baseline examination, evaluations every two months during treatment, and for up to six months after discontinuation. Suspicious lesions must be managed with excision and dermatopathological assessment.[7]
• Non-Cutaneous Malignancies: The mechanism of paradoxical activation may also promote the growth of internal malignancies driven by RAS mutations. If a patient develops a RAS-mutation-positive non-cutaneous malignancy, Encorafenib treatment should be permanently discontinued.[9]
• Hemorrhage: Major hemorrhagic events have been observed. In the pivotal COLUMBUS trial, hemorrhage of any grade occurred in 19% of patients receiving Encorafenib plus binimetinib, with Grade 3 or higher events in 3.2%. Critically, fatal intracranial hemorrhage was reported in 1.6% of patients, underscoring the seriousness of this risk.[11]
• Ocular Toxicity: Uveitis, including iritis and iridocyclitis, is a recognized adverse reaction.[7] Patients should be monitored for visual symptoms, and regular ophthalmologic evaluations are recommended. Management is grade-dependent, ranging from topical therapy for mild cases to withholding or permanently discontinuing Encorafenib for more severe or unresponsive cases.[7] Other ocular toxicities, such as serous retinopathy (retinal detachment), have also been reported with the combination therapy.[8]
• Cardiotoxicity:
• QT Prolongation: Encorafenib is associated with a dose-dependent prolongation of the QTc interval on the electrocardiogram (ECG).[10] This increases the risk of life-threatening cardiac arrhythmias. Management includes correcting electrolyte abnormalities (e.g., potassium, magnesium) and controlling cardiac risk factors prior to and during treatment. Regular ECG monitoring is required, and the drug must be withheld if the QTc interval exceeds 500 ms.[11]
• Cardiomyopathy: A decrease in left ventricular ejection fraction (LVEF), manifesting as cardiomyopathy, has been reported, particularly when Encorafenib is used with binimetinib.[8] Cardiac function should be assessed with an echocardiogram or MUGA scan at baseline and during treatment to detect any decline in heart function.[4]
• Embryo-Fetal Toxicity and Fertility Impairment: Encorafenib can cause harm to a developing fetus.[10] Females of reproductive potential must be advised of this risk and should use effective non-hormonal contraception during treatment and for a specified period after the final dose. Hormonal contraceptives may be rendered ineffective due to Encorafenib's drug-drug interaction profile.[10] Furthermore, Encorafenib may impair fertility in males due to effects on sperm production.[4]

Dose Modifications for Adverse Reactions

To manage toxicity, a structured dose reduction schedule is recommended. The starting dose and reduction steps vary by indication due to the different approved dosages. For melanoma or NSCLC, the standard 450 mg daily dose is first reduced to 300 mg, and then to 225 mg if needed. For metastatic CRC, the standard 300 mg daily dose is reduced to 225 mg, and then to 150 mg.[22] Specific guidelines for managing toxicities like uveitis and dermatologic reactions involve withholding the drug until resolution and then resuming at the same or a reduced dose, or permanent discontinuation for severe (Grade 4) events.[7]

Adverse Reaction	Severity (Grade)	Recommended Action for Melanoma / NSCLC (Starting Dose: 450 mg)	Recommended Action for CRC (Starting Dose: 300 mg)
General Toxicity	Grade 3	Withhold until Grade ≤1. Resume at next lower dose level (e.g., 300 mg).	Withhold until Grade ≤1. Resume at next lower dose level (e.g., 225 mg).
General Toxicity	Grade 4	Permanently discontinue.	Permanently discontinue.
Uveitis	Grade 1-2 (unresponsive) or Grade 3	Withhold for up to 6 weeks. If resolved, resume at same or reduced dose.	Withhold for up to 6 weeks. If resolved, resume at same or reduced dose.
Uveitis	Grade 4	Permanently discontinue.	Permanently discontinue.
Dermatologic Reaction	Grade 3	Withhold until Grade ≤1. Resume at same dose (first occurrence) or reduced dose (recurrent).	Withhold until Grade ≤1. Resume at same dose (first occurrence) or reduced dose (recurrent).
Dermatologic Reaction	Grade 4	Permanently discontinue.	Permanently discontinue.

Table 4: Selected Recommended Dose Modifications for Adverse Reactions. This table summarizes the structured approach to managing key toxicities with Encorafenib, providing actionable guidance for clinicians based on the specific indication and severity of the event.

Section 7: Drug-Drug Interactions and Contraindications

The clinical use of Encorafenib is complicated by a significant potential for drug-drug interactions, driven primarily by its metabolism through the cytochrome P450 system. These interactions are bidirectional, meaning Encorafenib's concentration can be altered by other drugs, and it can, in turn, alter the concentration of other drugs. Meticulous review of a patient's concomitant medications is therefore a critical safety measure.

Pharmacokinetic Interactions

The vast majority of clinically relevant interactions are pharmacokinetic and mediated by CYP enzymes.

• Effect of Other Drugs on Encorafenib: As a sensitive substrate of CYP3A4, Encorafenib's plasma concentration is highly dependent on the activity of this enzyme.[7]
• CYP3A4 Inhibitors: Co-administration with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, as well as grapefruit juice) will block the metabolism of Encorafenib, leading to increased plasma concentrations and a heightened risk of toxicity. This combination should be avoided. If unavoidable, a dose reduction of Encorafenib is mandatory.[9]
• CYP3A4 Inducers: Conversely, co-administration with strong or moderate inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) will accelerate the metabolism of Encorafenib, leading to decreased plasma concentrations and a potential loss of therapeutic efficacy. Concomitant use with these agents should be avoided.[9]
• Effect of Encorafenib on Other Drugs: Encorafenib is not merely a passive substrate; it is also an active inducer of several key metabolic enzymes, including CYP3A4, CYP2C9, and CYP2B6.[9] This means it can increase the clearance and thereby decrease the plasma concentrations and efficacy of any co-administered drugs that are substrates of these enzymes. This interaction is of paramount importance for hormonal contraceptives, which are metabolized by CYP3A4. Encorafenib can render them ineffective, necessitating the use of alternative, non-hormonal methods of contraception.[10] This inductive effect extends to a wide range of other medications, including certain anticoagulants, anticonvulsants, and other anticancer agents, requiring vigilant pharmacological surveillance by the clinical team.

Pharmacodynamic Interactions

In addition to pharmacokinetic interactions, there is a risk of additive pharmacodynamic effects. Because Encorafenib is known to cause dose-dependent QTc interval prolongation, its co-administration with other drugs that also prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, and antibiotics) should be avoided to prevent an increased risk of serious cardiac arrhythmias like Torsades de Pointes.[7]

Contraindications and Limitations of Use

According to the FDA-approved label, there are no absolute contraindications for Encorafenib.[11] However, there is a critical

Limitation of Use: Encorafenib is not indicated for the treatment of patients with wild-type BRAF cancers.[2] This is not a contraindication in the traditional sense but a strong warning based on its mechanism of action. Due to the risk of paradoxical MAPK pathway activation, using Encorafenib in this setting could potentially promote, rather than inhibit, tumor growth.

Concomitant Drug Type	Planned Encorafenib Dose (Melanoma/NSCLC)	Required Adjusted Dose	Planned Encorafenib Dose (CRC)	Required Adjusted Dose
Strong CYP3A4 Inhibitor	450 mg	150 mg (Reduce to 1/3)	300 mg	75 mg
Strong CYP3A4 Inhibitor	300 mg	75 mg	225 mg	75 mg
Moderate CYP3A4 Inhibitor	450 mg	225 mg (Reduce to 1/2)	300 mg	150 mg
Moderate CYP3A4 Inhibitor	300 mg	150 mg	225 mg	75 mg

Table 5: Recommended Encorafenib Dose Adjustments for Co-administration with CYP3A4 Inhibitors. This table provides specific, actionable guidance for modifying the Encorafenib dose when concurrent use of a CYP3A4 inhibitor is unavoidable, helping to prevent toxicity from elevated drug exposure.

Section 8: Regulatory and Developmental History

The journey of Encorafenib from a laboratory compound to a globally approved cancer therapy reflects a successful, multi-year effort in drug development and a series of strategic corporate and regulatory decisions.

Development and Commercialization

Encorafenib was originally developed by Array BioPharma, a biopharmaceutical company focused on small-molecule targeted therapies.[2] In 2019, Array BioPharma was acquired by

Pfizer Inc., which now holds the commercialization rights for Encorafenib (Braftovi) and its combination partner binimetinib (Mektovi) in the United States and Canada.[6] For most other territories, including Europe, Asia, and Latin America, exclusive commercialization rights were granted to

Pierre Fabre, a French pharmaceutical company.[19] This global partnership structure has facilitated the worldwide regulatory submissions and marketing of the drug.

Regulatory Approval Timeline

Encorafenib has received approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for multiple indications based on the strength of its clinical trial data.

U.S. Food and Drug Administration (FDA) Approvals:

• June 27, 2018: The FDA granted its initial approval for Encorafenib in combination with binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. This approval was based on the positive results of the COLUMBUS trial.[2]
• April 8, 2020: The indication was expanded to include the treatment of adult patients with previously treated, metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, in combination with cetuximab. This approval, based on the BEACON CRC trial, was granted under Priority Review and had received Breakthrough Therapy designation from the FDA.[6]
• October 11, 2023: The FDA approved the combination of Encorafenib with binimetinib for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, based on the PHAROS study.[2]
• December 20, 2024: The FDA granted accelerated approval for a first-line regimen of Encorafenib in combination with cetuximab and mFOLFOX6 chemotherapy for patients with BRAF V600E-mutant mCRC. This approval provides a new standard-of-care option for this patient population at an earlier stage of their disease.[2]

European Medicines Agency (EMA) Approvals:

• September 20, 2018: The EMA granted a marketing authorization for Braftovi (Encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.[28]
• Following the initial approval, the EMA's Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions and granted approvals for the colorectal cancer and non-small cell lung cancer indications, aligning with the data from the BEACON CRC and PHAROS trials, respectively.[19]

Section 9: Synthesis and Future Directions

Encorafenib has firmly established itself as a cornerstone of therapy for BRAF V600-mutant solid tumors. Its clinical success, however, is not that of a simple "magic bullet" but rather a testament to the maturation of targeted therapy into a sophisticated, multi-faceted discipline. The effective deployment of Encorafenib is inextricably dependent on three core principles: precision diagnostics, rational combination strategies, and vigilant pharmacological management.

The first principle, precision oncology, is absolute; the use of Encorafenib is entirely contingent on the pre-treatment identification of a sensitizing BRAF V600E or V600K mutation.[4] This mandates biomarker testing as a standard of care and underscores the shift away from histology-based treatment paradigms.

The second principle is that of rational combination. Encorafenib is not a monotherapy agent. Its efficacy and safety are optimized only when it is paired with a partner drug that mechanistically counters the tumor's specific escape pathways. In melanoma and NSCLC, this involves vertical blockade of the MAPK pathway with the MEK inhibitor binimetinib to overcome paradoxical activation. In colorectal cancer, it requires simultaneous blockade of the EGFR feedback loop with cetuximab. This partner-dependent identity highlights a deep understanding of tumor biology as a prerequisite for successful drug development.

The third principle is pharmacological vigilance. Encorafenib's complex pharmacokinetic profile, characterized by auto-induction and its dual role as both a substrate and an inducer of CYP3A4, creates a challenging landscape of drug-drug interactions. Safe administration requires a comprehensive and ongoing review of all concomitant medications, positioning the clinical pharmacist as an essential member of the oncology care team.

Looking forward, the therapeutic evolution of Encorafenib is ongoing, with active research aimed at expanding its utility and refining its application. Current clinical trials are exploring several key avenues:

• Novel Combinations: A major focus is on integrating Encorafenib-based regimens with immunotherapy. Trials are investigating the addition of PD-1 inhibitors like nivolumab to the Encorafenib and cetuximab backbone in BRAF-mutant CRC (e.g., NCT04017650).[29] Early data suggest that this triplet combination may be most beneficial when used in earlier lines of therapy rather than sequentially after progression on the doublet, indicating that overcoming resistance is a complex challenge.[29]
• Expansion to Earlier Disease Settings: Having proven its value in the metastatic setting, research is now exploring the use of Encorafenib in earlier stages of disease where the goal is curative. Trials are evaluating its role in the adjuvant setting for high-risk, resected melanoma and in the neoadjuvant setting to shrink tumors before surgery.[31] The recent accelerated approval in first-line mCRC is a major step in this direction.[6]
• New Indications: The success of Encorafenib in BRAF-mutant solid tumors has prompted investigation into hematologic malignancies. A clinical trial is currently active for patients with relapsed or refractory Hairy Cell Leukemia (HCL), a cancer where the BRAF V600E mutation is highly prevalent.[31]
• Real-World Evidence: Beyond the controlled environment of clinical trials, studies like the UK-EnBiRiM study (NCT07022457) are being conducted to gather real-world data on the effectiveness, tolerability, and quality-of-life impact of Encorafenib therapy in broader, more diverse patient populations.[33] This evidence will be crucial for understanding the true value and challenges of the treatment in routine clinical practice.

In conclusion, Encorafenib exemplifies the modern era of targeted cancer therapy. It is a potent, effective drug whose success is built upon a deep understanding of molecular biology, tumor resistance mechanisms, and clinical pharmacology. Its future development will likely focus on optimizing combination strategies, integrating it with immunotherapy, and moving its application to earlier stages of cancer, with the ultimate goal of further improving long-term outcomes for patients with BRAF-mutant malignancies.

Works cited

1. [Encorafenib | C22H27ClFN7O4S | CID 50922675 - PubChem, accessed July 25, 2025, ][https://pubchem.ncbi.nlm.nih.gov/compound/Encorafenib]
2. [Encorafenib - Wikipedia, accessed July 25, 2025, ][https://en.wikipedia.org/wiki/Encorafenib]
3. [Encorafenib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 25, 2025, ][https://go.drugbank.com/drugs/DB11718]
4. [Encorafenib (Braftovi®) | OncoLink, accessed July 25, 2025, ][https://www.oncolink.org/cancer\-treatment/oncolink\-rx/encorafenib\-braftovi\-R]
5. [A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [ 14C] encorafenib in healthy male subjects - PMC - PubMed Central, accessed July 25, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC10541456/]
6. [Braftovi (encorafenib) FDA Approval History - Drugs.com, accessed July 25, 2025, ][https://www.drugs.com/history/braftovi.html]
7. [Braftovi (encorafenib) dosing, indications, interactions, adverse ..., accessed July 25, 2025, ][https://reference.medscape.com/drug/braftovi\-encorafenib\-1000232]
8. [Mechanism Of Action | BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), accessed July 25, 2025, ][https://braftovi.pfizerpro.com/mektovi\-n/mechanism\-of\-action]
9. [Encorafenib: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 25, 2025, ][https://www.rxlist.com/encorafenib/generic\-drug.htm]
10. [BRAFTOVI® (encorafenib) capsules, for oral use - accessdata.fda.gov, accessed July 25, 2025, ][https://www.accessdata.fda.gov/drugsatfda\_docs/label/2020/210496s006lbl.pdf]
11. [BRAFTOVI (encorafenib) capsules, for oral use - accessdata.fda.gov, accessed July 25, 2025, ][https://www.accessdata.fda.gov/drugsatfda\_docs/label/2018/210496lbl.pdf]
12. [medlineplus.gov, accessed July 25, 2025, ][https://medlineplus.gov/druginfo/meds/a618040\.html\#:\~:text\=Encorafenib%20is%20in%20a%20class,the%20spread%20of%20cancer%20cells.]
13. [Encorafenib Uses, Side Effects & Warnings - Drugs.com, accessed July 25, 2025, ][https://www.drugs.com/mtm/encorafenib.html]
14. [ENCORAFENIB - precisionFDA, accessed July 25, 2025, ][https://precision.fda.gov/ginas/app/ui/substances/8L7891MRB6]
15. [Encorafenib | LGX818 | LGX-818 | CAS#1269440-17-6 | RAF inhibitor | MedKoo Biosciences, accessed July 25, 2025, ][https://www.medkoo.com/products/5588]
16. [Encorafenib (LGX818, CAS Number: 1269440-17-6) | Cayman Chemical, accessed July 25, 2025, ][https://www.caymanchem.com/product/16994/encorafenib]
17. [Encorafenib | CAS 1269440-17-6 | Cayman Chemical | Biomol.com, accessed July 25, 2025, ][https://www.biomol.com/products/chemicals/biochemicals/encorafenib\-cay16994\-500]
18. [Encorafenib - brand name list from Drugs.com, accessed July 25, 2025, ][https://www.drugs.com/ingredient/encorafenib.html]
19. [Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC), accessed July 25, 2025, ][https://eprints.aihta.at/1540/1/Fact%20Sheet%20Nr.187\.pdf]
20. [Encorafenib (LGX818) | BRAF Inhibitor - MedchemExpress.com, accessed July 25, 2025, ][https://www.medchemexpress.com/LGX818\.html]
21. [Encorafenib | 99.81%(HPLC) | In Stock | Raf inhibitor - Selleck Chemicals, accessed July 25, 2025, ][https://www.selleckchem.com/products/lgx818\.html]
22. [Encorafenib: uses, dosing, warnings, adverse events, interactions, accessed July 25, 2025, ][https://www.oncologynewscentral.com/drugs/monograph/175523\-318023/encorafenib\-oral]
23. [encorafenib - Cancer Care Ontario, accessed July 25, 2025, ][https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/74026]
24. [Encorafenib: MedlinePlus Drug Information, accessed July 25, 2025, ][https://medlineplus.gov/druginfo/meds/a618040\.html]
25. [Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) - PR Newswire, accessed July 25, 2025, ][https://www.prnewswire.com/news\-releases/array\-biopharma\-announces\-fda\-approval\-of\-braftovi\-encorafenib\-in\-combination\-with\-mektovi\-binimetinib\-300673447\.html]
26. [FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation, accessed July 25, 2025, ][https://www.fda.gov/drugs/resources\-information\-approved\-drugs/fda\-approves\-encorafenib\-combination\-cetuximab\-metastatic\-colorectal\-cancer\-braf\-v600e\-mutation]
27. [Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/​Cetuximab or Infusional 5-Fluorouracil (5-FU)/​Folinic Acid (FA)/​Irinotecan (FOLFIRI)/​Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) - ClinicalTrials.gov, accessed July 25, 2025, ][https://clinicaltrials.gov/study/NCT02928224]
28. [Braftovi | European Medicines Agency (EMA), accessed July 25, 2025, ][https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi]
29. [Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. - ASCO Publications, accessed July 25, 2025, ][https://ascopubs.org/doi/10\.1200/JCO.2025\.43\.4\_suppl.182]
30. [Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer, accessed July 25, 2025, ][https://www.mdanderson.org/patients\-family/diagnosis\-treatment/clinical\-trials/clinical\-trials\-index/clinical\-trials\-detail.ID2018\-0993\.html]
31. [Clinical Trials Using Encorafenib - NCI, accessed July 25, 2025, ][https://www.cancer.gov/research/participate/clinical\-trials/intervention/encorafenib?pn\=1]
32. [CLINICAL TRIAL / NCT04607421 - UChicago Medicine, accessed July 25, 2025, ][https://www.uchicagomedicine.org/find\-a\-clinical\-trial/clinical\-trial/irb211087]
33. [UK ENcorafenib and BInimetinib Real-world Study in Melanoma | ClinicalTrials.gov, accessed July 25, 2025, ][https://clinicaltrials.gov/study/NCT07022457]